SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-24-176585
Filing Date
2024-07-09
Accepted
2024-07-09 08:30:56
Documents
6
Period of Report
2024-08-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A d854372ddef14a.htm DEF 14A 366304
2 GRAPHIC g854372g00j01.jpg GRAPHIC 57079
3 GRAPHIC g854372g00p02.jpg GRAPHIC 54720
4 GRAPHIC g854372g23z17.jpg GRAPHIC 32308
5 GRAPHIC g854372g32g32.jpg GRAPHIC 289845
6 GRAPHIC g854372g33g33.jpg GRAPHIC 213533
  Complete submission text file 0001193125-24-176585.txt   1259871
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 134196017 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38130 | Film No.: 241106399
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)